Home  >  Research  >  Labs  >  Cancer Program  >  LABORATORY FOR CANCER MEDICINE

RESEARCH OVERVIEW

The Laboratory for Cancer Medicine team is driving a program of research that aims to discover new ways of treating cancer. The initial focus was on hormone dependent cancers, such as breast and prostate, but in recent years has expanded to include other cancers which may be associated with a poor prognosis – liver, colon, melanoma and head and neck. Our goal is to discover ways to abrogate the key pathways driving the growth of these tumors, with a view to translating some of these discoveries into new therapies.

From the mechanistic point of view, we have had a long-term interest in RNA biology and human disease, and this has led to discoveries of novel RNA-binding proteins that are involved in regulating hormone action in breast and prostate cancer. One of these, SLIRP, is a repressor of nuclear receptor hormone action that we are exploring in the context of prostate and colon cancer. Several other novel regulators of hormone action have been identified (eg. PACT), which are being investigated using genome-wide approaches in the context of their role as activators of prostate cancer growth.

Our interest in RNA biology was a natural fit for developing significant focus in microRNAs and cancer. microRNAs are short non-coding RNAs that play central roles in regulating normal cell growth. They offer great promise in cancer biology, as they present new avenues for diagnostics and therapeutics. Our studies have resulted in the discovery of several “tumor suppressor microRNAs” that suppress key signalling pathways in poor prognostic tumors, such as head and neck, melanoma and liver cancer. One of these, microRNA-7 or miR-7, acts a potent suppressor of cancer cell proliferation and invasion by targeting the EGF-receptor (EGFR) pathway. In parallel with our work to explore the functional biology of miR-7 in EGFR-driven tumors (head and neck, liver, prostate, glioma) using genome-wide approaches and preclinical models, we have established a spin-out company, miReven, which is focused on developing miR-7 as a potential ‘miR replacement therapy” for these cancers which we hope to move into early phase clinical trials in the forthcoming years. 

Professor Peter Leedman AO

Professor Peter Leedman AO

Cancer Medicine (Institute Director)

Read more

LATEST NEWS

Why walk 35kms when you could walk 70?

Breast cancer survivor pushes herself to say thank you Four years clear of cancer, Connie Nicoletti-Lewins is committed to supporting the people who work to solve cancer’s mysteries and develop new treatments. Inspired by Perth’s annual Walk for Women’s Cancer that raises funds for cancer researchers at the Harry Perkins…

Read More

Bioinformatics and high-performance computing evolution lead to better treatments for major diseases

It’s time to talk about bioinformatics and its influence on high-performance computing (HPC) as well as the importance of data analysis and interpretation in medical research. As part of Data Science Week events, 10-14 May, Perkins' bioinformatician Dr Elena Denisenko will join Dr Stuart Midgely, DUG CIO, physicist and high-performance…

Read More

Moorditj Mob walking to support cancer research

Indigenous medical scientist Danielle Headland is choosing to honour her late mother by supporting Perth’s Walk for Women’s Cancer to help cancer researchers find new treatments and solve the mysteries of the disease that claimed her mother’s life. Danielle’s mother succumbed to uterine cancer in 2013, two years after diagnosis.…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS